Onconetix announced that Realbotix, its pending acquisition target, has partnered with Bloom Procurement Services to launch a pilot program deploying socially assistive humanoid robots in UK care settings to address loneliness among elderly residents. Realbotix has been accredited as a supplier on Bloom's public sector marketplace. The acquisitio...

Onconetix Inc. (NASDAQ:ONCO) shares surged 23.65% to $0.38 in after-hours trading on Monday, reversing an 18.26% regular session decline. The biotech company reported clinical validation progress for Proclarix, a blood test for prostate cancer detection, with new peer-reviewed publications and initiation of a U.S. validation trial with Labcorp. H...

Onconetix shares surged 71.74% in premarket trading on Friday following the announcement of its acquisition of Realbotix, a company specializing in AI-driven humanoid robots. The acquisition is expected to enhance Onconetix's capabilities in AI and robotics. Additionally, the company implemented a 1-for-5 reverse stock split effective March 25. D...

Onconetix and Ocuvex Therapeutics have signed a definitive merger agreement where Onconetix will acquire Ocuvex, with Ocuvex shareholders receiving 90% of the combined company's equity. The transaction is expected to close in Q4 and aims to bring ophthalmic therapeutic assets to the public markets.

Tellurian Inc. shares rose sharply after Woodside Energy announced plans to acquire the company for $900 million. Several other stocks also saw significant pre-market movement, both positive and negative.